$翰宇药业(SZ300199)$排名前十的多肽药物包括:司美格鲁肽(Semaglutide)、度拉糖肽(Dulaglutide)、甘精胰岛素(Insulin Glargine)、门冬胰岛素(Insulin Aspart)、替尔泊肽(Tirzepatide)、利拉鲁肽(Liraglutide)、人胰岛素(Insulin Human)、赖脯胰岛素(Insulin Lispro)、罗米司亭(Romiplostim)、卡非佐米(Carfilzomib)。
Comparative Effectiveness of Semaglutide, Liraglutide, and Dulaglutide for All-Cause Mortality in Type 2 Diabetes (T2D) with and without CKD: An Emulated Clinical Trial Observational Studydoi:10.1681/ASN.2024gedej30fAmara SarwalUniversity of Utah Health, Salt Lake City, Utah, United States;Guo Wei...
该项目数据显示,在所有已完成的头对头临床研究中,与DPP-4抑制剂(sitagliptin,西格列汀)、SGLT-2抑制剂(empagliflozin,恩格列净)、GLP-1类似物(liraglutide利拉鲁肽,)、度拉鲁肽(dulaglutide)相比,口服索马鲁肽治疗的患者在研究结束时血糖水平降低幅度更大、平均体重下降更大。 PIONEER 6是PIONEER系列的一部分。这项...
减肥药市场上的竞争愈演愈烈,各大制药巨头纷纷布局,诺和诺德(Novo Nordisk)旗下:司美格鲁肽(Semaglutide)、利拉鲁肽(Liraglutide),礼来公司(Eli Lilly)旗下: 替尔泊肽(Tirzepatide)、德格列净(Dulaglutide),阿斯利康(AstraZeneca)旗下:艾塞那肽(Exenatide)等。从GLP-1R单靶点到GLP-1R/GCGR双靶点、GLP-1R/GIPR...
Comparative Effectiveness of Semaglutide, Liraglutide, and Dulaglutide for All-Cause Mortality in Type 2 Diabetes (T2D) with and without CKD: An Emulated C... A Sarwal,G Wei,SE Hartsell,... - 《Journal of the American Society of Nephrology》 被引量: 0发表: 2024年 Comparative Effectiveness...
Tell your doctor about all your other medicines, especiallyinsulinor other diabetes medicines, such asdulaglutide,exenatide,liraglutide,Byetta,Trulicity,Victoza, and others. Other drugs may affect semaglutide, including prescription and over-the-counter medicines,vitamins, andherbal products. Tell your doct...
B.I.D.: bis in die; Da: dalton; Dula: dulaglutide; EMA: European Medicines Agency; Exen: exenatide; FDA: Food and Drugs Administration; LAR: long-acting release; Lira: liraglutide; Lixi: lixisenatide; Sema: semaglutide Effect on glucose control, lipid panel and blood pressure GLP-1 RAs ...
Management of patients with type 2 diabetes with once-weekly semaglutide versus dulaglutide, exenatide ER, liraglutide and lixisenatide:A cost-effectiveness analysis in the Danish setting[J]. Diabetes Ther, 2019, 10(4):1297-1317. 更多...
Lancet Diabetes Endocrinol. 2020;8(5):392-406. Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39-50....
(MD: -1.08 kg [95%CI: -2.04, −0.12], P < 0.05). Oral semaglutide increased the incidence of adverse events (nausea, diarrhoea, dyspepsia, and vomiting) compared to placebo, liraglutide (1.2 mg), exenatide (ER, 2.0 mg), and dulaglutide 1.5 mg but not compared to subcutaneous ...